2024
Li-Fraumeni Syndrome: Imaging Features and Guidelines.
Gosangi B, Dixe de Oliveira Santo I, Keraliya A, Wang Y, Irugu D, Thomas R, Khandelwal A, Rubinowitz A, Bader A. Li-Fraumeni Syndrome: Imaging Features and Guidelines. Radio Graphics 2024, 44: e230202. PMID: 39024172, DOI: 10.1148/rg.230202.Peer-Reviewed Original ResearchConceptsLi-Fraumeni syndromeLifetime risk of cancerRare autosomal dominant familial cancer syndromeIncreased riskRisk of cancerTreated with total mastectomyAutosomal dominant familial cancer syndromeImaging features of tumorsFamilial cancer syndromeWhole-body MRIAnnual screeningFeatures of tumorsCancer syndromesLifetime riskP53 transcription factorLi-FraumeniAdrenocortical cancerTotal mastectomyPrimary cancerBreast malignancyImaging guidelinesBreast cancerGermline mutationsColon cancerManagement guidelinesDisorders with Ophthalmic and Thoracic Involvement.
Gosangi B, Lang P, Johnson M, Zukerman R, Tu L, Traube L, Bader A, Rubinowitz A. Disorders with Ophthalmic and Thoracic Involvement. Radio Graphics 2024, 44: e230132. PMID: 38870047, DOI: 10.1148/rg.230132.Peer-Reviewed Original ResearchConceptsClinical manifestationsExamination of family membersEhlers-Danlos syndromeAffecting patient outcomesAcute sarcoidosisOphthalmologic examinationThoracic symptomsDry eyeThoracic involvementOphthalmological symptomsOphthalmologic manifestationsEye symptomsMarfan syndromeSjogren's syndromeImaging findingsRadiological studiesLung diseasePatient outcomesEhlers-DanlosFamily membersMultimodal imagingSystem conditionsSyndromeThoracicSarcoidosis
2023
Cardiothoracic complications of immune checkpoint inhibitors
Gosangi B, Wang Y, Rubinowitz A, Kwan J, Traube L, Gange C, Bader A. Cardiothoracic complications of immune checkpoint inhibitors. Clinical Imaging 2023, 102: 98-108. PMID: 37659356, DOI: 10.1016/j.clinimag.2023.08.001.Peer-Reviewed Educational MaterialsConceptsImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsOverall survivalTumor responseAdverse effectsDevelopment of irAEsNovel adverse effectsImproved overall survivalOverall patient outcomesICI administrationHematologic malignanciesPatient outcomesSolid tumorsIrAEsCancer treatmentGreater mortalityComplicationsTherapySurvivalInhibitorsMyocarditisPneumonitisPatientsMalignancyQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
2014
Comparison of Perfusion, Diffusion, and MR Spectroscopy between Low-Grade Enhancing Pilocytic Astrocytomas and High-Grade Astrocytomas
de Fatima Vasco Aragao M, Law M, de Almeida D, Fatterpekar G, Delman B, Bader A, Pelaez M, Fowkes M, de Mello R, Valenca M. Comparison of Perfusion, Diffusion, and MR Spectroscopy between Low-Grade Enhancing Pilocytic Astrocytomas and High-Grade Astrocytomas. American Journal Of Neuroradiology 2014, 35: 1495-1502. PMID: 24699088, PMCID: PMC7964458, DOI: 10.3174/ajnr.a3905.Peer-Reviewed Original Research